Disclosed are an o-phenyl chalcone compounds and preparation methods and uses thereof. The o-phenyl chalcone compounds are capable of inhibiting the aggregation of microtubules in tumor cells and influencing the mitosis of the cells, and has a high antitumor activity. The compounds also have inhibitory activity against proliferation on various tumor cells, such as a human ovary cancer cell A2780, a human colon cancer cell HCT8, a human breast cancer cell MCF7, a human lung cancer cell A549, a human colon cancer cell SW480, a human nasopharyngeal carcinoma cell CNE2, a human liver cancer cell HepG2 and the like at nanomole concentrations.

The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating GPR40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs. That is, the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention can be co-administered with other drugs and can promote the activation of GPR40 protein significantly, so that the composition comprising the same as an active ingredient can be efficiently used as a pharmaceutical composition for the prevention and treatment of metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X, etc.

The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating GPR40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs. That is, the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention can be co-administered with other drugs and can promote the activation of GPR40 protein significantly, so that the composition comprising the same as an active ingredient can be efficiently used as a pharmaceutical composition for the prevention and treatment of metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X, etc.

The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating GPR40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs. That is, the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention can be co-administered with other drugs and can promote the activation of GPR40 protein significantly, so that the composition comprising the same as an active ingredient can be efficiently used as a pharmaceutical composition for the prevention and treatment of metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X, etc.

A solid-supported palladium(II) complex which catalyzes the Mizoroki-Heck coupling reaction efficiently and a method of employing the solid-supported palladium(II) complex to synthesize cinnamic acid and derivatives thereof. The solid-supported palladium(II) complex is also stable and can be recycled without significantly losing catalytic activity.

A solid-supported palladium(II) complex which catalyzes the Mizoroki-Heck coupling reaction efficiently and a method of employing the solid-supported palladium(II) complex to synthesize cinnamic acid and derivatives thereof. The solid-supported palladium(II) complex is also stable and can be recycled without significantly losing catalytic activity.

The present invention discloses a valorization method of a flux containing undesired D-lactic acid (ester(s)) in the production process of L-polylactic acid, the production thereof comprising: oligomerisation (30) of a substantially pure L-lactic acid feed; cyclisation (40) of the lactic acid oligomers, thereby obtaining lactides and a first residual stream transferred, at least partially, to a transesterification (80) and a hydrolysis (90) step; lactide purification (50), thereby obtaining purified lactides comprising L-lactide and meso-lactide, a second and a third residual stream, wherein the second residual stream is transferred, at least partially, to the oligomerisation (30) step and the third residual stream is transferred, at least partially, to a transesterification (80) and a hydrolysis step (90); polymerisation (60) of the purified lactides into poly lactic acid; purification (70) of the poly lactic acid, thereby obtaining purified polylactic acid comprising substantially L-polylactic acid and unreacted L-lactide, unreacted meso-lactide and impurities transferred, at least partially, to the lactide purification step (50); transesterification (80) and hydrolysis (90) of the at least partially transferred first and third residual streams, thereby obtaining a fourth and a fifth residual stream which are used, at least partially, as a base for the synthesis of molecules insensitive to the optical isometry D or L of lactic acid (esters).

The present invention discloses a valorization method of a flux containing undesired D-lactic acid (ester(s)) in the production process of L-polylactic acid, the production thereof comprising: oligomerisation (30) of a substantially pure L-lactic acid feed; cyclisation (40) of the lactic acid oligomers, thereby obtaining lactides and a first residual stream transferred, at least partially, to a transesterification (80) and a hydrolysis (90) step; lactide purification (50), thereby obtaining purified lactides comprising L-lactide and meso-lactide, a second and a third residual stream, wherein the second residual stream is transferred, at least partially, to the oligomerisation (30) step and the third residual stream is transferred, at least partially, to a transesterification (80) and a hydrolysis step (90); polymerisation (60) of the purified lactides into poly lactic acid; purification (70) of the poly lactic acid, thereby obtaining purified polylactic acid comprising substantially L-polylactic acid and unreacted L-lactide, unreacted meso-lactide and impurities transferred, at least partially, to the lactide purification step (50); transesterification (80) and hydrolysis (90) of the at least partially transferred first and third residual streams, thereby obtaining a fourth and a fifth residual stream which are used, at least partially, as a base for the synthesis of molecules insensitive to the optical isometry D or L of lactic acid (esters).

A solid-supported palladium(II) complex which catalyzes the Mizoroki-Heck coupling reaction efficiently and a method of employing the solid-supported palladium(II) complex to synthesize cinnamic acid and derivatives thereof. The solid-supported palladium(II) complex is also stable and can be recycled without significantly losing catalytic activity.

A solid-supported palladium(II) complex which catalyzes the Mizoroki-Heck coupling reaction efficiently and a method of employing the solid-supported palladium(II) complex to synthesize cinnamic acid and derivatives thereof. The solid-supported palladium(II) complex is also stable and can be recycled without significantly losing catalytic activity.